Precision Drilling (PDS) Company Overview

This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release.

PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech.

“The global drill bit market is expanding rapidly, driven by rising demand from industries like oil & gas, mining, aerospace, and construction for durable, high-performance drilling technologies.” “The global drill bit market is expanding rapidly, driven by rising demand from industries like oil & gas, mining, aerospace, and construction for durable, high-performance drilling technologies.”

Precision Drilling's Q3 report shows strong performance in Canada, where rig demand is at multiyear highs. While the U.S. market remains a weakness, Precision Drilling is generating adequate margins on its super spec rigs that remain in tight supply. When U.S. activity rebounds, Precision Drilling will benefit from the much higher pricing that will be necessary to balance the market.

EMV Capital (AIM:EMVC) has noted the clinical progress update from portfolio company PDS Biotechnology alongside its third-quarter update. Frank Bedu-Addo, PDS chief executive, said:  "Since our last update in August, we have been actively engaged with investors and clinicians to discuss our strategy and funding requirements for our VERSATILE-003 Phase 3 trial of Versamune® HPV + pembrolizumab compared to pembrolizumab as a potential treatment for first-line recurrent/metastatic HPV16-positive head and neck squamous cell cancer (HNSCC).

PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time.

Precision Drilling Corporation (NYSE:PDS ) Q3 2024 Earnings Conference Call October 30, 2024 1:00 PM ET Company Participants Lavonne Zdunich - VP, IR Carey Ford - CFO Kevin Neveu - President and CEO Conference Call Participants Kurt Hallead - Benchmark Waqar Syed - ATB Capital Markets Sean Mitchell - Daniel Energy Partners John Gibson - BMO Capital Markets Keith Mackey - RBC Capital Markets Aaron MacNeil - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Precision Drilling Corporation 2024 Third Quarter Conference Call.

Precision Drilling (PDS) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.55 per share. This compares to earnings of $1.08 per share a year ago.

CALGARY, Alberta, Oct. 29, 2024 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release. This news release contains references to certain Financial Measures and Ratios, including Adjusted EBITDA (earnings before income taxes, loss (gain) on investments and other assets, gain on repurchase of unsecured senior notes, finance charges, foreign exchange, gain on asset disposals and depreciation and amortization), Funds Provided by (Used in) Operations, Net Capital Spending, Working Capital and Total Long-term Financial Liabilities. These terms do not have standardized meanings prescribed under International Financial Reporting Standards ( IFRS ) Accounting Standards and may not be comparable to similar measures used by other companies. See “Financial Measures and Ratios” later in this news release.